DSIJ Mindshare

FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.

Abhishek Wani 0 157 Article rating: 4.7

Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.

Sensex & Nifty End Flat, Midcap & Smallcap Indices Down Upto 1.7 Per Cent

The Nifty 50 ended marginally lower by 0.01 per cent at 22,545.05, and the Sensex inched up by 0.01 per cent to close at 74,612.43.

Manoj Reddy Sama 0 163 Article rating: 1.0

Market breadth was heavily negative, with 571 advances and 2,292 declines, indicating a strong negative sentiment prevailed among investors.

RSS
First7879808183858687Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR